Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

Biological Psychiatry

Volumn 45, Issue 4, 1999, Pages 403-411

  Breier, Alan ^a   Hamilton, Susan H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Haloperidol; Nonresponders; Olanzapine; Treatment resistant schizophrenia

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; AKATHISIA, DRUG-INDUCED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; BENZODIAZEPINES; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0033558072     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00291-1     Document Type: Article

References (58)

1. Baldacchino A.M., Stubbs J.H., Nevison-Andrews D. The use of olanzapine in non-compliant or treatment-resistant clozapine populations in hospital. Pharm J. 260:1998;207-209.
2. Barnes T.R.E. A rating scale for drug-induced akathisia. Br J Psychiatry. 154:1989;672-676.
3. Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S., et al. Olanzapine versus placebo and haloperidol Acute phase results of the North American double-blind olanzapine trial . Neuropsychopharmacology. 14:1996;111-123.
4. Beuzen J-N, Birkett MA, Kiesler GM (1998): An investigation of subgroup effects in a study of olanzapine vs. clozapine in the treatment of resistant schizophrenic patients [abstract]. 11th ECNP Congress, Paris, France.
5. Birchwood M., Mason R., Macmillan F., Healy J. Depression, demoralization and control over psychotic illness A comparison of depressed and non-depressed patients with a chronic psychosis . Psychol Med. 23:1993;387-395.
6. Bjorndal N., Bjerre M., Gerlach J., Kristjansen P., Magelund G., Oestrich I.H., et al. High dosage haloperidol therapy in chronic schizophrenic patients A double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin . Psychopharmacology (Berl). 67:1980;17-23.
7. Breier A., Schreiber J.L., Dyer J., Pickar D. National institute of mental health longitudinal study of chronic schizophrenia Prognosis and predictors of outcome . Arch Gen Psychiatry. 48:1991;239-246.
8. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 151:1994;20-26.
9. Buchanan R.W., Brandes M., Breier A. Treating negative symptoms. Breier A. The New Pharmacotherapy of Schizophrenia. 1st ed. 1996;179-204 American Psychiatric Press, Washington, DC.
10. Bymaster F.P., Rasmussen K., Calligaro D.O., Nelson D.L., DeLapp N.W., Wong T.D., et al. In vitro and in vivo biochemistry of olanzapine A novel, atypical antipsychotic drug . J Clin Psychiatry. 58:1997;28-36.
11. Carpenter W.T.J., Conley R.R., Buchanan R.W., Breier A., Tamminga C.A. Patient response and resource management Another view of clozapine treatment of schizophrenia . Am J Psychiatry. 152:1995;827-832.
12. Casey D.E. Clozapine Neuroleptic-induced EPS and tardive dyskinesia . Psychopharmacology (Berl). 99:(suppl):1989;S47-S53.
13. Conley R.R., Schulz C., Baker R.W., Collins J.F., Bell J.A. Clozapine efficacy in schizophrenic nonresponders. Psychopharmacol Bull. 24:1988;269-274.
14. Conley R.R., Tomminga C.A., Bartko J.J., Richardson C., Peszkes M., Lingle J., Hegerty J., Love R., Goanoris C., Zarcamba S. Olanzapine vs. chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 155:1998;914-920.
15. Crawford A.M.K., Beasley C.M., Tollefson G.D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 26:1997;41-54.
16. Dassa D., Kaladjian A., Azorin J.M., Giudicelli S. Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry. 163:1993;822-824.
17. Fitton A., Heel R.C. Clozapine, a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs. 40:1990;722-747.
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976;US Department of Health, Education and Welfare, Bethesda, MD.
19. Hegarty J.D., Baldessarini R.J., Tohen M., Waternaux C., Oepen G. One hundred years of schizophrenia A meta-analysis of the outcome literature . Am J Psychiatry. 151:1994;1409-1416.
20. Hirsch S.R., Jolley A.G. The dysphoric syndrome in schizophrenia and its implication for relapse. Br J Psychiatry. 155:1989;46-50.
21. Kane J.M. Treatment-resistant schizophrenic patients. J Clin Psychiatry. 57:1996;35-40.
22. Kane J.M., Marder S.R. Psychopharmacologic treatment of schizophrenia. Schizophr Bull. 19:1993;287-302.
23. Kane J.M., Cooper T.B., Sachar E.J., Halpern F.S., Bailine S. Clozapine Plasma levels and prolactin response . Psychopharmacology (Berl). 73:1981;184-187.
24. Kane J.M., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic A double-blind comparison with chlorpromazine . Arch Gen Psychiatry. 45:1988;789-796.
25. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. 1986;Multi-Health Systems, North Tonawanda, NY.
26. Kinon B.J., Kane J.M., Johns C., Perovich R., Ismi M., Koreen A., et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull. 29:1993;309-314.
27. Lindenmayer J.-P., Grochowski S., Mabugat L. Clozapine effects on positive and negative symptoms A six-month trial in treatment-refractory schizophrenics . J Clin Psychopharmacol. 14:1994;201-204.
28. Marder S.R. Management of treatment-resistant patients with schizophrenia. J Clin Psychiatry. 57:1996;26-30.
29. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835.
30. Martin J., Gomez J.-C., Garcia-Bernardo E., Cuesta M., Alvarez E., Gurpegui M., et al. Olanzapine in treatment-refractory schizophrenia Results of an open-label study . J Clin Psychiatry. 58:1997;479-483.
31. Mattes J.A. Clozapine for refractory schizophrenia An open study of 14 patients treated up to 2 years . J Clin Psychiatry. 50:1989;389-391.
32. Meltzer H.Y., Bastani B., Kwon K.Y., Ramirez L.F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant patients I. Preliminary report . Psychopharmacology (Berl). 99:1989;S68-S72.
33. Meltzer H.Y., Burnett S., Bastani B., Ramirez L.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry. 41:1990;892-897.
34. Meltzer H.Y., Cola P., Way L., Thompson P.A., Bastani B., Davies M.A., et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry. 150:1993;1630-1638.
35. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 134:1979;382-389.
36. Moore N.A., Calligaro D.O., Wong T.D., Bymaster F., Tye N.C. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs. 2:1993;281-293.
37. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep. 10:1962;799-812.
38. Owen R.R., Beake B.J., Marby D., Dessain E.C., Cole J.O. Response to clozapine in chronic psychotic patients. Psychopharmacol Bull. 25:1989;253-256.
39. Parsa M.A., Ramirez L.F., Loula E.C., Meltzer H.Y. Effect of clozapine on psychotic depression and parkinsonism. J Clin Psychopharmacol. 11:1991;330-331. [letter].
40. Pickar D., Owen R.R., Litman R.E., Konicki E., Gutierrez R., Rapaport M.H. Clinical and biologic response to clozapine in patients with schizophrenia Crossover comparison with fluphenazine . Arch Gen Psychiatry. 49:1992;345-353.
41. Ranjan R., Meltzer H.Y. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry. 40:1996;253-258.
42. Remington G., Pollock B., Voineskos G., Reed K., Coulter K. Acutely psychotic patients receiving high-dose haloperidol therapy. J Clin Psychopharmacol. 13:1993;41-45.
43. Revicki D.A., Luce B.R., Weschler J.M., Brown R.E., Adler M.A. Cost-effectiveness of clozapine for treatment-resistant schizophrenics. Hosp Community Psychiatry. 41:1990;850-854.
44. Richelson E. Preclinical pharmacology of neuroleptics Focus on new generation compounds . J Clin Psychiatry. 57:1996;4-11.
45. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med. 337:1997;809-815.
46. SAS/STAT User's Guide. 4th ed. 1990;SAS Institute Inc, Cary, NC.
47. Schooler N.M., Kane J.M. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry. 39:1982;486-487. [letter].
48. Schooler N., Kane J., Marder S., Baker R., Safferman A., Wirshing W., et al. Efficacy of clozapine vs haloperidol in a long term clinical trial Preliminary findings . Schizophr Res. 15:1995;165. [abstract].
49. Simpson G.M., Annable L. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 212:1970;11-19.
50. Siris S.G. Depression and schizophrenia. Hirsch S.R., Weinberger D.R. Schizophrenia. 1995;128-145 Blackwell Science, Oxford, England.
51. Small J.G., Milstein V., Marhenke J.D., Hall D.D., Kellams J.J. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry. 48:1987;263-267.
52. Stockton M.E., Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology. 14:1996;97-104.
53. Szymanski S., Masiar S., Mayerhoff D., Loebel A., Geisler S., Pollack S., et al. Clozapine response in treatment-refractory first-episode schizophrenia. Biol Psychiatry. 35:1994;278-280.
54. Thompson C. The use of high-dose antipsychotic medication. Br J Psychiatry. 164:1994;448-458.
55. Tollefson G.D., Beasley C.M., Tran P., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders Results of an international collaborative trial . Am J Psychiatry. 154:1997;457-465.
56. Tollefson G.D., Sanger T.M., Lu Y., Thieme M.E. Depressive signs and symptoms in schizophrenia A trial of olanzapine and haloperidol . Arch Gen Psychiatry. 55:1998;250-258.
57. Tran P., Dellva M.A., Tollefson G.D., Beasley C.M., Potvin J.H., Kiesler G.M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry. 58:1997;205-211.
58. Wolkowitz O.M., Pickar D. Benzodiazepines in the treatment of schizophrenia A review and reappraisal . Am J Psychiatry. 148:1991;714-726.